Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT ID: NCT06573593
Last Updated: 2024-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2024-07-29
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata
NCT05861401
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
NCT05255237
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
NCT01950780
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT02553330
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tofacitinib treated group
In the real-world settings, patients with AA treated with tofacitinib.
Tofacitinib
In the real-world settings, patients with AA treated with tofacitinib.
Baritinib treated group
In the real-world settings, patients with AA treated with baritinib.
Baricitinib
In the real-world settings, patients with AA treated with Baricitinib.
Ruxolitinib treated group
In the real-world settings, patients with AA treated with ruxolitinib
Ruxolitinib
In the real-world settings, patients with AA treated with Ruxolitinib.
Upadacitinib treated group
In the real-world settings, patients with AA treated with upadacitinib.
Upadacitinib
In the real-world settings, patients with AA treated with Upadacitinib.
Abrocitinib treated group
In the real-world settings, patients with AA treated with abhicitinib.
Abrocitinib
In the real-world settings, patients with AA treated with Abrocitinib.
Ritlecitinib treated group
In the real-world settings, patients with AA treated with ritlecitinib.
Ritlecitinib
In the real-world settings, patients with AA treated with Ritlecitinib.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tofacitinib
In the real-world settings, patients with AA treated with tofacitinib.
Baricitinib
In the real-world settings, patients with AA treated with Baricitinib.
Ruxolitinib
In the real-world settings, patients with AA treated with Ruxolitinib.
Upadacitinib
In the real-world settings, patients with AA treated with Upadacitinib.
Abrocitinib
In the real-world settings, patients with AA treated with Abrocitinib.
Ritlecitinib
In the real-world settings, patients with AA treated with Ritlecitinib.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with alopecia areata according to AA guideline
* AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
Exclusion Criteria
* Other alopecia
* Other diseases may induce alopecia including psoriasis, lichen planus, et al.
* Unable to estimate SALT score at baseline or at follow-up
* Patients are participating in other clinical trials
2 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xianjie Wu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20240699
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.